Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Xu, Jian Ming ^a   Han, Yu ^a   Li, Yue Min ^a   Zhao, Chuan Hua ^a   Wang, Yan ^a   Paradiso, Angelo ^b  

^a Beijing 307 Hospital   (China)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEFITINIB; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG FATALITY; DRY SKIN; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRURITUS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; ADENOCARCINOMA; CANCER STAGING; CHINA; LUNG TUMOR; MORTALITY; PATHOLOGY; PATIENT SELECTION; SURVIVAL;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PATIENT SELECTION; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 33846661392     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-288     Document Type: Article

References (29)

1. Alberola V Camps C Provencio M Isla D Rosell R Vadell C Bover I Ruiz-Casado A Azaqra P Jimenez U Gonzalez-Larriba JL Diz P Cardenal F Artal A Carrato A morales S Sanchez JJ de las Penas A Felip E lopez-Vivanco G Spanish Lung Cancer group Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial J Clin Oncol 2003 21 3207-3213 10.1200/ JCO.2003.12.038 12947054
2. Cullen MH Billingham LJ Woodroffe CM Chetiyawardana AD Gower NH Joshi R Ferry DR Rudd RM Spiro SG Cook JE Trask C Bessell E Connolly CK Tobias J Souhami RL Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life J Clin Oncol 1999 17 3188-3194 10506617
3. Klastersky J Paesmans M Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: Review of literature results Lung Cancer 2001 34 suppl 4 95-101 10.1016/ S0169-5002(01)00383-X
4. Georgoulias V Papadakis E Alexopoulos A Tsiafaki X Rapti A Veslemes M Palamidas P Vlachonikolis I Greek Oncology Cooperative Group (GOCG) for Lung cancer Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial Lancet 2001 357 1478-1484 10.1016/S0140-6736(00)04644-4 11377599
5. Georgoulias V Ardavanis A Agelidou A Agelidou M Chandrinos V Tsaroucha E Toumbis M Kouroussis C Syrigos K Polyzos A Samaras N Papakotoulas P Christofilakis C Ziras N Alegakis A Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial J Clin Oncol 2004 22 2602-2609 10.1200/JCO.2004.11.004 15226327
6. Bunn-PA J Kelly K New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions Clin Cancer Res 1998 4 1087-1100 9607565
7. Isobe T Herbst RS Onn A Current management of advanced non-small cell lung cancer: Targeted therapy Semin Oncol 2005 32 b315 328 10.1053/ j.seminoncol.2005.02.016
8. Fukuoka M Yano S Giaccone G tamura T Nakagawa K Douillard JY Nishiwaki Y Vansteenkiste J Kudoh S Rischin D Eek R Horai T Noda K Takata I Smit E Averbuch S Macleod A Fevereislova A Dong RP Baselga J Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 2003 21 2237-2246 10.1200/JCO.2003.10.038 12748244
9. Veronese ML Algazy K Bearn L Eaby B Alavi J Evans T Stevenson JP Shults J Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): The expanded access protocol experience at the University of Pennsylvania Cancer Invest 2005 23 296-302 10.1081/CNV-61528 16100941
10. Miller VA Kris MG Shah NS Patel J Azzoli C Gomez J Krug LM Pao W Rizvi N Pizzo B Tyson L Venkatraman E Ben-Porat L Memoli N Zakowski M Rusch V Heelan RT Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 2004 22 1103-1109 10.1200/JCO.2004.08.158 15020612
11. Giaccone G Herbst RS Manegold C Scagliotti G Rosell R Miller V Natale RB Schiller JH Von Pawel J Pluzanska A Gatzemeier U Grous J Ochs JS Averbuch S Wolf MK Rennie P Fandi A Johnson DH Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1 J Clin Oncol 2004 22 777-784 10.1200/ JCO.2004.08.001 14990632
12. Herbst RS Giaccone G Schiller JH Natale RB Miller V Manegold C Scagliotti G Rosell R Oliff I Reeves JA Wolf MK Krebs AD Averbuch SD Ochs JS Grous J Fandi A Johnson DH Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 J Clin Oncol 2004 22 785-794 10.1200/ JCO.2004.07.215 14990633
13. Mattingly RR Milstein M Mirkin BL Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistance human neuroblastoma cells Cell Signal 2001 13 499-505 10.1016/ S0898-6568(01)00173-5 11516625
14. Naruse I Ohmori T Ao Y Fukumoto H Kuroki T Mori M Saijo N nishio K Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo Int J Cancer 2002 98 310-315 10.1002/ijc.10173 11857424
15. Xu JM Paradiso A McLeod HL Evaluation of epidermal growth factor receptor tyrosine kinase inhibitor combined with chemotherapy: Is there a need for a more rational design? Eur J Cancer 2004 40 1807-1809 10.1016/j.ejca.2004.04.028 15288280
16. Green S Weiss G Southwest Oncology Group standard response criteria. Endpoint definitions and toxicity criteria Invest New Drug 1992 10 239-253 10.1007/BF00944177
17. Cella DF Eton DT Fairclough DL What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592 J Clin Epidemiol 2002 55 285-295 10.1016/ S0895-4356(01)00477-2 11864800
18. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53 457-481 10.2307/2281868
19. Kosmidis P Mylonakis N Nicolaides C Kalophonos C Samantas E Boukovinas J Fountzilas G Skarlos D Economopoulos T Tsavdaridis D Papakostas P Bacoyiannis C Dimopoulos M Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial J Clin Oncol 2002 20 3578-3585 10.1200/ JCO.2002.12.112 12202657
20. Frasci G Panza N Comella P Nicolella GP Natale M Manzione I Bilancia D Cioffi R Maiorino L De Cataldis G Belli M Micillo E Massidda B Lorusso V De Lena M Carpagnano F Contu A Pusceddu G Comella G Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study J Clin Oncol 1999 17 2316-2325 10561293
21. Bonomi PD Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer Clin Lung Cancer 2004 6 154 161 15555216
22. Androulakis N Kouroussis C Kakolyris S Tzannes S Papadakis E Papadimitriou C Geroyianni A Georgopoulou T Dimopoulou I Souglakos J Kotsakis A Vardakis N Hatzidaki D Georgoulias V Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel based chemotherapy: A multicenetr phase II study Ann Oncol 1998 9 1127-1130 10.1023/A:1008497322508 9834827
23. Chang AY DeVore R Johnson D Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small-cell lung cancer Semin Oncol 1996 23 19-21 8610231
24. Gridelli C Airoma G Incoronato P Pepe R Palazzolo G Rossi A Bianco AR Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer Cancer Chemotherapy Pharmacol 1992 30 212-214 10.1007/BF00686314
25. Xu JM Azzariti A Severino M Lu B Colucci G Paradiso A Characterization of sequence- dependent synergy between ZD1839 and oxaliplatin Biochem Pharmacol 2003 66 547-559 10.1016/S0006-2952(03)00291-0
26. Xu JM Azzariti A Colucci G Paradiso A Effect of gefitinib ('Iressa', ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines Cancer Chemother Pharmacol 2003 52 442-448 10.1007/ s00280-003-0687-8 13680161
27. Shepherd FA Second-line chemotherapy for non-small cell lung cancer Expert Rev Anticancer Ther 2003 3 435-442 10.1586/14737140.3.4.435 12934656
28. Chen YM Perng RP Lee CS Lin WC Tsai CM Whang-Peng J Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy Am J Clin Oncol 2003 26 567-570 10.1097/01.coc.0000045808.39041.49 14663373
29. Mott FE Cable CT Sharma N Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer Clin Lung Cancer 2003 5 174-176 14667273